LataMed AI Corp. (OTC: LMED), a digital health and artificial intelligence technology company focused on telehealth infrastructure and healthcare analytics for emerging markets, announced today that it expects to formally submit a corporate action request to FINRA seeking approval of a proposed five-for-one (5-for-1) forward stock split, along with proportional increases in authorized common and preferred stock. The company stated that the proposed split is intended to support long-term operational scalability, strategic flexibility, capitalization planning, and future growth initiatives as it expands telehealth infrastructure, healthcare analytics integration, and commercialization efforts throughout Latin America and other targeted emerging markets.
The proposed forward stock split would apply proportionally to all issued and outstanding shares of common stock and outstanding preferred stock designations, including Series C Voting Preferred Stock. The company emphasized that the action does not involve debt restructuring, recapitalization, or reduction in shareholder ownership percentages. No fractional shares are expected to be issued; any fractional interests would be rounded up to the nearest whole share per board resolutions.
Management noted that the forward stock split is part of a broader effort to align the company's capital structure with its transition into digital healthcare infrastructure and AI-driven telehealth operations. Dr. Kevin Rodan Levy, Chief Executive Officer, stated: "As we continue advancing our operational and commercialization initiatives throughout Latin America, we believe this proposed forward stock split and proportional capital structure expansion may support broader long-term strategic flexibility, operational scalability, and future growth initiatives as we continue building our healthcare technology platform."
The company recently commenced initial operational activities for its telehealth platform infrastructure in Venezuela, following regulatory authorization from the Ministerio del Poder Popular para la Salud and Servicio Autonomo de Contraloria Sanitaria (SACS). This milestone marks a key step in LataMed AI's strategy to deploy scalable telehealth solutions in emerging markets.
The proposed forward stock split remains subject to FINRA review and approval, completion of applicable regulatory processing, and final corporate implementation procedures. No assurance can be provided regarding the timing or ultimate effectiveness of the proposed corporate action. For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
As a development-stage enterprise, LataMed AI has not generated revenues from its current business operations and faces risks typical of early-stage companies, including reliance on financing, regulatory approvals, and successful commercialization. The company's ability to execute its business plan depends on various factors, including FINRA's decision on the proposed stock split.
